Nucana Plc shares surge 45% in premarket after receiving Nasdaq delisting notice and strong industry performance.

Nucana Plc surged 45% in premarket trading, driven by a 0.59% overall increase in the European ADR market and a 19% rise in the stock price of UK and Irish healthcare companies. The company, a clinical-stage biopharmaceutical firm, focuses on developing new cancer drugs using ProTide technology to enhance the efficacy and safety of existing therapies. Additionally, NuCana received a delisting notice from Nasdaq due to its stock price falling below $0.10 for 10 consecutive days, but has announced plans to request a hearing to temporarily halt the delisting process.